FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366769357> ?p ?o ?g. }

• W4366769357 abstract "This study evaluated the efficacy and safety of baricitinib (Janus kinase-1/2 inhibitor), in adult and pediatric Japanese patients with Nakajo-Nishimura syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (NNS/CANDLE), stimulator of interferon genes-associated vasculopathy with onset during infancy (SAVI), or Aicardi-Goutières syndrome (AGS).A Phase 2/3, multicenter, open-label study (NCT04517253) was conducted across 52 weeks. Primary efficacy endpoint assessed the change in mean daily diary score (DDS) from baseline to the end of primary treatment period. Other efficacy endpoints included change in mean DDS to the end of maintenance period, daily corticosteroid use, Physician's Global Assessment of Disease Activity (PGA) scores, and daily symptom-specific score (DSSS) from baseline to primary and maintenance treatment periods. All treatment-emergent adverse events (TEAEs) that occurred postdosing were recorded.Overall, 9 patients (5 with NNS, 3 with SAVI, and 1 with AGS) were enrolled; 55.6% were females, mean age was 26 years, and mean corticosteroid use/weight was 0.2 mg/kg. At the end of primary treatment period, mean DDS decreased from baseline in patients with NNS/CANDLE (0.22) and SAVI (0.21) and increased in the patient with AGS (0.07). At the end of maintenance treatment period, mean DDS decreased from baseline in patients with NNS/CANDLE (0.18) and SAVI (0.27) and increased in the patient with AGS (0.04). Mean percent corticosteroid use decreased by 18.4% in 3 out of 5 patients with NNS/CANDLE and 62.9% in 1 out of 3 patients with SAVI. Mean PGA score decreased from baseline in patients with NNS/CANDLE (1.60), SAVI (1.33), and AGS (1.0), and mean DSSS improved from baseline. All patients reported ≥ 1 TEAE. Frequently reported AEs included BK polyomavirus detection (3; 33.3%), increased blood creatine phosphokinase (2; 22.2%), anemia (2; 22.2%), and upper respiratory tract infection (2; 22.2%). Three (33.3%) patients reported serious adverse events, 1 of which was related to study drug. One patient with SAVI died due to intracranial hemorrhage, which was not related to study drug.Baricitinib may offer a potential therapeutic option for patients with NNS/CANDLE, SAVI, and AGS, with a positive benefit/risk profile in a vulnerable patient population with multiple comorbidities.NLM clinicaltrials.gov, NCT04517253 . Registered 18 August 2020." @default.
• W4366769357 created "2023-04-25" @default.
• W4366769357 creator A5003653534 @default.
• W4366769357 creator A5013201631 @default.
• W4366769357 creator A5058583144 @default.
• W4366769357 creator A5066821710 @default.
• W4366769357 creator A5073478620 @default.
• W4366769357 date "2023-04-22" @default.
• W4366769357 modified "2023-09-26" @default.
• W4366769357 title "Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS)" @default.
• W4366769357 cites W1789511037 @default.
• W4366769357 cites W1968047575 @default.
• W4366769357 cites W1974656027 @default.
• W4366769357 cites W1976028208 @default.
• W4366769357 cites W1980705501 @default.
• W4366769357 cites W2015310325 @default.
• W4366769357 cites W2063675796 @default.
• W4366769357 cites W2066635545 @default.
• W4366769357 cites W2080685621 @default.
• W4366769357 cites W2123414080 @default.
• W4366769357 cites W2124075611 @default.
• W4366769357 cites W2513658500 @default.
• W4366769357 cites W2523917120 @default.
• W4366769357 cites W2768689142 @default.
• W4366769357 cites W2769096731 @default.
• W4366769357 cites W2796581040 @default.
• W4366769357 cites W3082027965 @default.
• W4366769357 cites W4225468931 @default.
• W4366769357 cites W4247009636 @default.
• W4366769357 doi "https://doi.org/10.1186/s12969-023-00817-8" @default.
• W4366769357 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37087470" @default.
• W4366769357 hasPublicationYear "2023" @default.
• W4366769357 type Work @default.
• W4366769357 citedByCount "0" @default.
• W4366769357 crossrefType "journal-article" @default.
• W4366769357 hasAuthorship W4366769357A5003653534 @default.
• W4366769357 hasAuthorship W4366769357A5013201631 @default.
• W4366769357 hasAuthorship W4366769357A5058583144 @default.
• W4366769357 hasAuthorship W4366769357A5066821710 @default.
• W4366769357 hasAuthorship W4366769357A5073478620 @default.
• W4366769357 hasBestOaLocation W43667693571 @default.
• W4366769357 hasConcept C126322002 @default.
• W4366769357 hasConcept C197934379 @default.
• W4366769357 hasConcept C203092338 @default.
• W4366769357 hasConcept C2776804153 @default.
• W4366769357 hasConcept C535046627 @default.
• W4366769357 hasConcept C71924100 @default.
• W4366769357 hasConceptScore W4366769357C126322002 @default.
• W4366769357 hasConceptScore W4366769357C197934379 @default.
• W4366769357 hasConceptScore W4366769357C203092338 @default.
• W4366769357 hasConceptScore W4366769357C2776804153 @default.
• W4366769357 hasConceptScore W4366769357C535046627 @default.
• W4366769357 hasConceptScore W4366769357C71924100 @default.
• W4366769357 hasFunder F4320333624 @default.
• W4366769357 hasIssue "1" @default.
• W4366769357 hasLocation W43667693571 @default.
• W4366769357 hasLocation W43667693572 @default.
• W4366769357 hasLocation W43667693573 @default.
• W4366769357 hasOpenAccess W4366769357 @default.
• W4366769357 hasPrimaryLocation W43667693571 @default.
• W4366769357 hasRelatedWork W1582154474 @default.
• W4366769357 hasRelatedWork W1966919723 @default.
• W4366769357 hasRelatedWork W1972768471 @default.
• W4366769357 hasRelatedWork W2413531578 @default.
• W4366769357 hasRelatedWork W2425686475 @default.
• W4366769357 hasRelatedWork W2913883964 @default.
• W4366769357 hasRelatedWork W2981730245 @default.
• W4366769357 hasRelatedWork W2984050611 @default.
• W4366769357 hasRelatedWork W3128136124 @default.
• W4366769357 hasRelatedWork W4247438754 @default.
• W4366769357 hasVolume "21" @default.
• W4366769357 isParatext "false" @default.
• W4366769357 isRetracted "false" @default.
• W4366769357 workType "article" @default.